Polypeptide With Localisation/Targeting Motif TRIZ Cases

See how CAR and BiTE constructs use anti-TK1 scFv to direct T cells against intracellular tumor

Golgi-targeted NODC adds positively charged oligosaccharides to plant cell walls, improving dye uptake and reactivity without slowing root growth.

rAAV delivery of soluble Flt-1 enables sustained VEGF modulation in the eye, reducing repeat injections and retinal fluid.

Specific RSV F protein mutations in an RNA vaccine improve prefusion stability, neutralizing antibodies, and viral load reduction.

Selective ALK7:ActRIIB heteromultimers block TGF-beta superfamily ligands to reduce body weight while limiting off-target effects.

Dual CD90/CD326 adapters trigger CAR immune cells only above a combined threshold, improving tumor specificity while limiting off-tumor toxicity.

A CBD and His dual-tag lets TEV protease be purified and removed after cleavage even when the target protein has high histidine content.

B2M-derived promoters tune CAR expression to limit cytokine storms while preserving T-cell proliferation and longer therapeutic activity.

Engineered anti-CD47 antibodies preserve tumor-targeting immune activity while reducing red blood cell binding and normal-cell toxicity.

JAK or mTOR inhibitors reduce cytokine release syndrome in T-cell engager therapies while preserving target cell killing.

Engineered CD123/IL7Ra CAR lymphocytes improve AML cell killing and persistence while sparing normal tissue from hematopoietic toxicity.

A novel Cas sigma enzyme uses single-guide RNA and broader PAM recognition to improve editing specificity while reducing off-target effects.

Specific CLDN18.2 binding enables ADCC and CDC against gastric tumor cells, expanding targeted treatment beyond limited HER2 and PD-1 options.

Anti-GPC2 scFv CARs improve recognition and killing of cancer cells with native GPC2 expression while limiting toxicity.

Adjusting CCR7+CD45RA+ and CD8+ T-cell ratios improves CAR T durability and response while limiting inflammation-related toxicity.

MMP-activated ACPP-HK2 peptides penetrate tumor cells, redistribute HK2, and induce rapid cell death while limiting toxicity in healthy tissues.

Combining anti-CD19 and anti-CD20 binding motifs helps engineered T cells recognize and kill evasive leukemia and lymphoma cells more effectively.

Fully human anti-CD19 CARs improve T-cell persistence and CD19 cell killing while reducing immune rejection in B-cell cancer therapy.

Modified CD147-binding CAR-T receptors improve solid tumor killing and persistence while using inducible safety controls to limit toxicity.

A GGGGS-linked deaminase-Cas12a fusion enables targeted base editing in plants while reducing off-target edits and avoiding double-strand cuts.

Species-matched AAV EPO delivery enables stable anemia treatment in cats and dogs while avoiding immune reactions and frequent injections.

Engineered NKG2D CAR T cells target TNBC ligands to improve tumor cell killing and inhibit tumor growth where standard therapies fall short.

Targeting the Tn-MUC1 glycoepitope helps CAR T cells attack solid tumors more selectively while limiting off-tumor toxicity.

A human-dog consensus telomerase vaccine broadens HLA coverage and boosts cross-reactive antitumor immune responses.

Cell type-specific promoters and Sun1-GFP nuclear tagging enable magnetic purification of target nuclei from mixed tissue for clearer genomics.

CMV-specific CARs redirect CD8+ T cells to recognize and kill infected cells, overcoming the complexity of autologous CMV immunotherapy.

Tumor-specific peptides from TE-exon fusion transcripts improve MHC-targeted immune responses while limiting healthy tissue targeting.

Chemically synthesized human-derived peptide modules improve UniCAR targeting stability while reducing immunogenic tags and production complexity.

Engineered memory-like CAR-NK cells target the NPM1c-MHC I neoepitope to improve persistence, tumor killing, and specificity with lower off-target toxicity.

MyD88-CD40 costimulatory signaling helps CAR T cells avoid poor persistence and weak activation, improving proliferation and tumor cell killing.

By blocking CLEC2 binding to the SARS-CoV-2 RBD, this fusion protein suppresses NET formation, thrombosis, and pulmonary inflammation.

Bi-specific CAR-T cells target CD19, CD20, and CD22 to improve hematologic cancer killing while reducing antigen escape and severe side effects.

Targeted PH20 amino acid substitutions and terminal deletions improve thermal stability, expression, and refolding while preserving activity.

Targeted spike-protein mutations lock the prefusion state, preserving ACE2 binding while improving stability and immunogenicity for vaccines and screening.

Engineered dual CAR-T cells target both CD20 and CD22 to counter antigen escape, strengthen immune synapses, and reduce relapse.

Synthetic promoters with multiple TME response elements activate CAR expression in tumors while limiting off-target toxicity in normal tissues.

A modular membrane-anchored fluorescent probe turns target-state changes into polarization signals for real-time live-cell detection.

Engineered immune cells use a CD300c-binding CAR to selectively target cancer cells and suppress growth and metastasis with fewer adverse effects.

Klf4 overexpression restores exhausted CD8 T cell function and proliferation, improving anticancer activity in CAR-T and related cell therapies.

Parallel chimeric activating receptors separate co-stimulatory domains to sustain T-cell potency, IL-2 release, and repeated tumour killing.

EMCN-specific CAR and scFv constructs improve AML cell targeting while reducing off-target effects on normal cells.

Sequence-specific TALE blocks plus a light-strand nick enable predictable mtDNA deletions without relying on inefficient double-strand break repair.

A nickase-exonuclease base editor enables single-strand editing in nuclear, mitochondrial, and chloroplast DNA with high purity and few indels.

By linking anti-PD-1 antibodies with IL-15 and IL-15Rα, this case boosts tumor-site immune activation while reducing systemic toxicity.

Engineered Cas12L proteins and guide RNAs improve sequence-specific nucleic acid cleavage with higher specificity and fewer off-target edits.

Self-assembling β-peptide hydrogels cushion stem cells during delivery, improving viability and host tissue integration for stroke therapy.

Engineered EGFRvIII-binding antibody fragments improve CAR cell targeting in glioblastoma while reducing off-target toxicity and supporting persistence.

Dual CD20 and BCMA targeting in one CAR improves B cell depletion when single-antigen therapies miss efficacy endpoints in autoimmune disease.

Immune checkpoint-modified extracellular vesicles improve targeting stability and reduce off-target organ accumulation during therapeutic delivery.

An scFv-CAR targeting KRAS G12V presented by HLA-A*02:01 improves tumor specificity while reducing off-target toxicity in solid tumors.

Dual CD20 and BCMA binding in engineered T cells improves B cell depletion and cytotoxicity where prior antibody therapies fell short.

Modified splice sites and codon usage help BCMA CARs maintain stable surface expression, lower tonic signaling, and resist soluble BCMA.

Partial endogenous mtDNA reduction enables gentler mitochondrial transfer, improving recipient cell function while avoiding slow, harmful depletion steps.

Engineered immune cells convert a prodrug at tumor sites to boost cancer killing while limiting systemic toxicity and off-target effects.

A human LRRC24-derived transmembrane peptide improves intracellular cargo delivery by boosting cell penetration while reducing immune response.

A small alpha-helical epitope tag paired with high-affinity nanobodies enables reliable protein detection, imaging, immobilization, and purification.

By linking anti-PD-1 antibodies with IL-15 and the IL-15Rα sushi domain, this case boosts local immune activation while limiting systemic toxicity.

A single OR-gate CAR recognizes either CD19 or CD20, helping T cells kill B-cell tumors despite antigen loss and reducing relapse risk.

Fully human CD19 antibody scFv reduces CAR-T immunogenicity, improving compatibility and supporting longer cell survival.

A TAT-linked AJ007 fusion polypeptide enables eye drops to cross the blood-ocular barrier and treat choroidal neovascularization without intravitreal injection.

S1P receptor modulators sequester CAR cells in lymphoid tissues to improve persistence and anti-tumor activity while reducing CRS and MAS.

By combining translocation, binding, and killing domains, chimeric klebicins broaden Klebsiella targeting and lower resistance frequency.

Barcoded high-throughput screening links T-cell receptors to matching antigens faster, using phagocytosis or trogocytosis to recover interacting pairs.

Dual-target CAR T cells bind CD19 and CD79B to limit antigen escape in B cell malignancies while maintaining strong tumor killing.

CAR-expressing immune cells use spike-binding receptor modules to improve recognition and killing of SARS-CoV-2-infected cells.

Targeted dCas9 or zinc finger repressors silence PCSK9 without DNA cleavage, reducing off-target risk and supporting safer cholesterol control.

Targeted promoter and 5'-UTR mutations raise protein output in Bacillus cells while preserving core promoter function.

Single-domain CD20 binders replace larger antibody formats to improve CAR stability and specificity while helping reduce toxicity risks.

A selective Trop2-binding peptide enables targeted drug delivery, imaging, and diagnosis for resistant cancers while limiting side effects.

A CD70-binding CAR expands CAR-T targeting beyond CD19, enabling specific killing of CD70-positive tumors and stronger cytokine release.

RINF knockdown helps CAR-T cells persist longer in vivo, boosting tumor eradication while avoiding higher transformation risk.

Using two CLTX peptides in γδ T-cell CARs boosts GBM killing and persistence while supporting chemotherapy resistance.

Biomimetic 5-module T cell receptors use surrogate co-receptors and Lck association to improve specificity and sensitivity while limiting cytokine release.

A human IL-10-derived peptide improves macrophage delivery of biologically active substances while reducing immune response and cargo disruption.

Cytokine-binding polypeptides neutralize TNF-α, IFN-γ, and IL-1 to reduce CRS toxicity during immunotherapy while preserving efficacy.

Engineered Siglec-7 or Siglec-9 chimeric receptors convert sialic-acid tumor binding from NK-cell inhibition into anti-tumor activation.

Fc-linked neuraminidase inhibitors boost immune-cell viral clearance and extend half-life to address resistant influenza and prolonged shedding.

Genetically modified mammalian cells produce properly folded, glycosylated SARS-CoV-2 RBD at high yield for diagnostics and therapeutics.

Targeted IL-18 mutations reduce IL-18BP binding while preserving receptor signaling, improving immune activation and anti-tumor response.

Novel peptide sequences improve cell membrane penetration and enable delivery of polynucleotides or polypeptides into cells.

Engineered humanized EGFRvIII CAR-T cells bypass tumor-driven immune suppression and improve targeting of EGFRvIII-positive cancers.

FAP-targeted CAR-T cells reduce skeletal muscle fibrosis and improve AAV gene delivery in muscular dystrophy tissue.

Repeated CD19 CAR-NK dosing with lymphodepletion and optional anti-CD20 therapy improves blood cancer response while limiting harm to healthy cells.

Fc fusion, FcRn-enhancing mutations, and sialylated glycosylation extend ENPP1 half-life to reduce dosing burden in calcification therapy.

PTPN2 inhibition boosts lymphoid cell anti-tumor activity in solid tumors while limiting toxicity from high-dose immune cell therapy.

Modified apolipoproteins with targeting bodies guide lipid nanoparticles to specific cells while reducing off-target delivery and immune responses.

Engineered CARs target disease-associated macrophage markers to modulate inflammation and fibrosis in autoimmune and fibrotic conditions.

Peptides from the BNIP3 N-terminus block BNIP3-BAX activity at mitochondria to limit cell death during reperfusion injury.

Fully human HER3-binding antibodies improve tumor targeting by avoiding EGFR and HER2 cross-reactivity while supporting signaling inhibition.

A high-affinity IL-23R binder in a CAR enables targeted immune-cell activation at inflammation sites while minimizing tonic signaling.

A 14-24 amino acid N-terminal spacer improves E. coli secretion and signal peptide cleavage for recombinant Protein A expression.

Amino acid substitutions in CRISPR nucleases improve mature-cell delivery, raise editing efficiency, and reduce off-target events.

Genetically boosting AP-1 activity helps engineered T cells resist exhaustion, sustain killing function, and improve memory formation.

Specific PCR markers identify the EE-GH7 cotton event while supporting stable dual tolerance to glyphosate and HPPD inhibitor herbicides.

Targeted CD3ζ tyrosine-site mutations tune CAR signaling to improve CAR-T persistence and amplification while reducing toxic side effects.

BCMA-targeting CAR-T and CAR-NK cells selectively deplete mature B cells to deliver longer autoimmune control with fewer side effects.

Immobilized anti-CD3/CD28 stimulation on a chromatography column selects and activates T cells, cutting handling time and contamination risk.

Modified Cas12a with dual gRNAs targets T-rich PAM sites to improve editing precision and efficiency while lowering off-target effects.

Feedback-insensitive GNE in a GlycoDelete cell background boosts homogeneous sialyl-LacNAc glycoprotein production.

IL7Fc armored CAR-T cells secrete IL-7 to boost T-cell recruitment, persistence, and cytotoxicity against solid tumors.

Epigenetic editors target B2M with DNMT and repressor domains to durably silence transcription while avoiding DNA breaks and off-target risks.

Psoralen-UVA DNA crosslinking stops CAR-NK cell division after expansion while preserving tumor killing and reducing toxicity.

Specific CDR-based CLL-1 CAR constructs improve immune cell recognition and killing of leukemia cells while managing receptor complexity.

Labeled CAR-binding peptides and magnetic particles isolate high-purity CAR T-cells without inert EGF receptor domains that hinder detection.

Multi-target CAR T-cells combine CD33, CLL1, CD123, and FLT3 binding to reduce AML antigen escape and relapse.

Targeted Dda helicase mutations and a CsgG-CsgF pore complex stabilize dwell times and cut nanopore sequencing errors below 10%.

Cyclic cell-penetrating CAL-PDZ peptides block CFTR degradation pathways, improving mutant CFTR stability and ion transport activity.

Aerosol mRNA delivery to bovine preputial tissue drives local antibody expression against Tritrichomonas foetus without culling infected bulls.

FAST polypeptides embedded in liposomes mediate targeted membrane fusion for siRNA delivery while reducing cytotoxicity and non-specific release.